
Moon Young Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3593183/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq1 1 0	.7843 1245 rg BT	/Overlock i
2	Autoimmune Hepatitis Following Vaccination for SARS-Cov-2 in Korea: Coincidence or Autoimmunity?. Journal of Korean Medical Science, 2022, 37, e116.	2.5	18
3	Application of ultrasound for the diagnosis of cirrhosis/portal hypertension. Journal of Medical Ultrasonics (2001), 2022, 49, 321-331.	1.3	7
4	The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatology International, 2021, 15, 424-436.	4.2	3
5	Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients. Hepatology International, 2021, 15, 1207-1214.	4.2	8
6	Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol. Journal of Korean Medical Science, 2021, 36, e145.	2.5	8
7	Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. PLoS ONE, 2021, 16, e0258229.	2.5	28
8	Association Between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea. Journal of Preventive Medicine and Public Health, 2021, 54, 412-421.	1.9	5
9	Interaction between the tumor microenvironment and resection margin in different gross types of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 648-653.	2.8	9
10	Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. Liver International, 2020, 40, 3083-3092.	3.9	11
11	Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score. Diagnostics, 2020, 10, 805.	2.6	1
12	Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics. International Journal of Stem Cells, 2020, 13, 394-403.	1.8	6
13	Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine, 2020, 35, 1074-1083.	1.7	3
14	Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives. Gut and Liver, 2020, 14, 306-315.	2.9	47
15	Application of Baveno Criteria and Modified Baveno Criteria with Shear-wave Elastography in Compensated Advanced Chronic Liver Disease. Journal of Korean Medical Science, 2020, 35, e249.	2.5	5
16	Prediction of the varices needing treatment with nonâ€invasive tests in patients with compensated advanced chronic liver disease. Liver International, 2019, 39, 1071-1079.	3.9	33
17	The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. Journal of Korean Medical Science, 2019, 34, e223.	2.5	4
18	Perspectives on Acute Hepatitis A Control in Korea. Journal of Korean Medical Science, 2019, 34, e230.	2.5	8

Moon Young Kim

#	Article	IF	CITATIONS
19	Contrast-enhanced Ultrasonography: The Third Modality for Differentiation of Liver Mass. Journal of Liver Cancer, 2019, 19, 91-96.	1.1	1
20	The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. World Journal of Surgery, 2018, 42, 1514-1522.	1.6	14
21	Adipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochemical and Biophysical Research Communications, 2018, 498, 988-995.	2.1	61
22	Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatology International, 2018, 12, 112-121.	4.2	17
23	Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 910-917.	2.8	19
24	Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study. Digestive Diseases and Sciences, 2018, 63, 248-256.	2.3	9
25	Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean Journal of Internal Medicine, 2018, 33, 453-461.	1.7	63
26	The Impact of Sarcopenia and Its Rate of Change on Prognostic Value of Liver Cirrhosis. Journal of Korean Medical Science, 2018, 33, e334.	2.5	2
27	Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 860-870.	7.3	101
28	Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2017, 62, 1067-1079.	2.3	37
29	Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0186990.	2.5	237
30	Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis. Clinical and Molecular Hepatology, 2017, 23, 34-41.	8.9	51
31	Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut and Liver, 2017, 11, 702-710.	2.9	27
32	Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Gut and Liver, 2016, 10, 109.	2.9	28
33	Transplantation with autologous bone marrowâ€derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology, 2016, 64, 2185-2197.	7.3	213
34	Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatology International, 2016, 10, 819-828.	4.2	47
35	The meaning of gross tumor type in the aspects of cytokeratin 19 expression and resection margin in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 206-212.	2.8	4
36	Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Translational Medicine, 2016, 5, 1247-1256.	3.3	35

Moon Young Kim

#	Article	IF	CITATIONS
37	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Clinical and Molecular Hepatology, 2016, 22, 443-449.	8.9	10
38	Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. Journal of Korean Medical Science, 2015, 30, 1405.	2.5	52
39	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS ONE, 2015, 10, e0133935.	2.5	36
40	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver International, 2015, 35, 2246-2255.	3.9	66
41	Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World Journal of Gastroenterology, 2014, 20, 4300.	3.3	98
42	Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease. Journal of Korean Medical Science, 2014, 29, 392.	2.5	10
43	Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clinical and Molecular Hepatology, 2014, 20, 376.	8.9	19
44	Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. BMC Gastroenterology, 2014, 14, 198.	2.0	63
45	Histological improvement following administration of autologous bone marrowâ€derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver International, 2014, 34, 33-41.	3.9	159
46	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology, 2014, 60, 954-963.	7.3	169
47	The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Clinical and Molecular Hepatology, 2013, 19, 370.	8.9	48
48	Revision and update on clinical practice guideline for liver cirrhosis. The Korean Journal of Hepatology, 2012, 18, 1.	1.5	120
49	Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea. Clinical and Molecular Hepatology, 2012, 18, 391.	8.9	12
50	Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. Journal of Hepatology, 2011, 55, 1004-1009.	3.7	152
51	Retinoid Induces the Degradation of Corneodesmosomes and Downregulation of Corneodesmosomal Cadherins: Implications on the Mechanism of Retinoid-induced Desquamation. Annals of Dermatology, 2011, 23, 439.	0.9	16
52	Portal Hypertensive Gastropathy: Correlation with Portal Hypertension and Prognosis in Cirrhosis. Digestive Diseases and Sciences, 2010, 55, 3561-3567.	2.3	53
53	Hemodynamic alterations in cirrhosis and portal hypertension. The Korean Journal of Hepatology, 2010, 16, 347.	1.5	79
54	Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2009, 21, 1241-1246.	1.6	47

#	Article	IF	CITATIONS
55	Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver International, 2007, 27, 1103-1110.	3.9	65
56	Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective Study. Gut and Liver, 2007, 1, 159-164.	2.9	16